ACCEL-SILDENAFIL TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
27-12-2018
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
SILDENAFIL (SILDENAFIL CITRATE)
Tillgänglig från:
ACCEL PHARMA INC
ATC-kod:
G04BE03
INN (International namn):
SILDENAFIL
Dos:
100MG
Läkemedelsform:
TABLET
Sammansättning:
SILDENAFIL (SILDENAFIL CITRATE) 100MG
Administreringssätt:
ORAL
Enheter i paketet:
4/8
Receptbelagda typ:
Prescription
Terapiområde:
PHOSPHODIESTERASE TYPE 5 INHIBITORS
Produktsammanfattning:
Active ingredient group (AIG) number: 0136261003; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2018-08-03
Produktens egenskaper
_________________________________________________________________________________
_
_ACCEL-SILDENAFIL (sildenafil citrate) Product Monograph _
_Page 1 of 49_
PRODUCT MONOGRAPH
PR
ACCEL-SILDENAFIL
sildenafil as sildenafil citrate
Tablets 25 mg, 50 mg and 100 mg
House Standard
cGMP-Specific Phosphodiesterase Type 5 Inhibitor
Treatment of Erectile Dysfunction
Accel Pharma Inc.
99 Place Frontenac
Pointe-Claire, Quebec
H9R 4Z7
Date of Revision:
December 27, 2018
SUBMISSION CONTROL NO: 222236
_________________________________________________________________________________
_
_ACCEL-SILDENAFIL (sildenafil citrate) Product Monograph _
_Page 2 of 49_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
3
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE REACTIONS
......................................................................................................
7
DRUG INTERACTIONS
....................................................................................................
12
DOSAGE AND ADMINISTRATION
................................................................................
15
OVERDOSAGE
..................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 17
STORAGE AND STABILITY
............................................................................................
20
SPECIAL HANDLING INSTRUCTIONS
.........................................................................
20
DOSAGE FORMS, CO
Läs hela dokumentet
